Journal article

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Daver, N. G., Vyas, P., Kambhampati, S., Al Malki, M. M., Larson, R. A., Asch, A. S., Mannis, G. N., Chai-Ho, W., Tanaka, T. N., Bradley, T. J., Jeyakumar, D., Wang, E. S., Xing, G., Chao, M., Ramsingh, G., Renard, C., Lal, I., Zeidner, J. F., & Sallman, D. A. (2022). Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results. Journal of Clinical Oncology, 40(S16).

MLA Style

Daver, N. G., et al. “Tolerability and Efficacy of the First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine in Frontline TP53m AML Patients: Phase 1b Results.” Journal of Clinical Oncology, vol. 40, no. S16, American Society of Clinical Oncology, 2022.

Chicago Style

Daver, NG, P Vyas, S Kambhampati, MM Al Malki, RA Larson, AS Asch, GN Mannis, et al. 2022. “Tolerability and Efficacy of the First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine in Frontline TP53m AML Patients: Phase 1b Results.” Journal of Clinical Oncology 40 (S16).
Share
Print

Access Document

Publisher copy:: 10.1200/jco.2022.40.16_suppl.7020

Authors

+ Daver, NG More by this author

Role:: Author

+ Vyas, P More by this author

Institution:: University of Oxford
Division:: MSD
Department:: RDM
Sub department:: RDM Clinical Laboratory Sciences
Oxford college:: St Anne's College
Role:: Author
ORCID:: 0000-0003-3931-0914

+ Kambhampati, S More by this author

Role:: Author

+ Al Malki, MM More by this author

Role:: Author

+ Larson, RA More by this author

Role:: Author

More authors...

+ Gilead Sciences (United States) More from this funder

Funder identifier:: https://ror.org/056546b03

Publisher:: American Society of Clinical Oncology
Journal:: Journal of Clinical Oncology More from this journal
Volume:: 40
Issue:: S16
Article number:: 7020
Publication date:: 2022-06-01
DOI:: 10.1200/jco.2022.40.16_suppl.7020
EISSN:: 1527-7755
ISSN:: 0732-183X

Language:: English
Keywords:: cancer

rare diseases

clinical research

immunotherapy

orphan drug

hematology

pediatric cancer

clinical trials and supportive activities

pediatric
Pubs id:: 1858360
Local pid:: pubs:1858360
Deposit date:: 2024-07-08

Terms of use

Copyright holder:: American Society of Clinical Oncology
Copyright date:: 2022
Rights statement:: © 2022 by American Society of Clinical Oncology.

Licence:: Terms and Conditions of Use for Oxford University Research Archive

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP